Learning Hub Central

2026 SPS Seattle | 505(b)(2): From Opportunity Assessment to Implementation Best Practices

0.00 Credits

1 Chapter

Pharmacology

Free

2026 SPS Seattle | HER’s First – Zongertinib’s Push to First-Line Setting in HER2 Positive Non-Small Cell Lung Cancer

0.00 Credits

1 Chapter

Pharmacology

Free

2026 SPS Seattle | Expanding the Myasthenia Gravis Treatment Landscape: Introduction to Nipocalimab

0.00 Credits

1 Chapter

Pharmacology

Free

2026 SPS Seattle | Isatuximab Subcutaneous by On-Body Injector vs. Isatuximab Intravenous Plus Pomalidomide & Dexamethasone

0.00 Credits

1 Chapter

Pharmacology

Free

2026 SPS Seattle | Expanding the Horizon: Sunvozertinib in NSCLC with EGFR Exon 20 Insertions

0.00 Credits

1 Chapter

Pharmacology

Free

2026 SPS Seattle | Make Way for HER, Datopotamab Deruxtecan Use in Breast Cancer and Non-Small Cell Lung Cancer

0.00 Credits

1 Chapter

Pharmacology

Free

2026 SPS Seattle | HELIOS B Clinical Trial: Vutrisiran in the Management of Transthyretin-Mediated Amyloidosis Cardiomyopathy Patients

0.00 Credits

1 Chapter

Pharmacology

Free

2026 SPS Seattle | Gedatolisib: A New Therapeutic Option in HR+/HER2− Advanced Breast Cancer

0.00 Credits

1 Chapter

Pharmacology

Free

2026 SPS Seattle | The Role of Artificial Intelligence (AI) in Drug Formulary Management

0.00 Credits

1 Chapter

Pharmacology

Free

2026 SPS Seattle | Caplacizumab in the Management of Thrombotic Thrombocytopenic Purpura, A Review of Real-World Evidence & MAYARI Clinical Trial

0.00 Credits

1 Chapter

Pharmacology

Free

2026 SPS Seattle | Taletrectinib Pushing Progression-Free-Survival (PFS) Boundaries in the ROS1+ Non-Small Cell Lung Cancer Setting (NSCLC)

0.00 Credits

1 Chapter

Pharmacology

Free

2026 SPS Seattle | Measuring the Impact of Specialty Clinical Pharmacists

0.00 Credits

1 Chapter

Pharmacology

Free

2026 SPS Seattle | CMS Drug Price Negotiations, Site Neutrality and Proposed ASP – 33.4%; Waves of Provider Reimbursement Cuts

0.00 Credits

1 Chapter

Pharmacology

Free

2026 SPS Twin Cities | Hyaluronidase Delivering New Subcutaneous Dosage Forms Throughout Various Therapeutic Areas: A Dive into Clinical, Safety, Practice and Economic Considerations

0.00 Credits

1 Chapter

Pharmacology

Free

2026 SPS Twin Cities | CMS Drug Price Negotiations Through Maximum Fair Price (MFP): Access & Practice Considerations Now & Then

0.00 Credits

1 Chapter

Pharmacology

Free

2026 SPS Twin Cities | Datopotamab Deruxtecan Therapy Considerations in the Management of Unresectable or Metastatic Hormone Receptor-Positive

0.00 Credits

1 Chapter

Pharmacology

Free

2026 SPS Twin Cities | The Evolving Role of Caplacizumab in the Management of Thrombotic Thrombocytopenic Purpura (TTP)

0.00 Credits

1 Chapter

Pharmacology

Free

2026 SPS Twin Cities | Beyond FOLFIRINOX: Updates in the Pancreatic Cancer Space

0.00 Credits

1 Chapter

Pharmacology

Free

2026 SPS Twin Cities | Treosulfan Clinical and Practice Considerations in the Management of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome

0.00 Credits

1 Chapter

Pharmacology

Free

2026 SPS Twin Cities | Gedatolisib in the Management of HR+/HER2-/PIK3CA Wild-Type Advanced Breast Cancer

0.00 Credits

1 Chapter

Pharmacology

Free

2026 SPS Twin Cities | Emerging 505(b)(2) Therapeutic Optionality: From Opportunity Assessment to Implementation Best Practices

0.00 Credits

1 Chapter

Pharmacology

Free

2026 SPS Twin Cities | Telisotuzumab Clinical Considerations in the Management of Non-Small Cell Lung Cancer (NSCLC)

0.00 Credits

1 Chapter

Pharmacology

Free

2026 SPS Twin Cities | Beyond Steroids: Precision Biologic Approaches to Immune Related Adverse Event Management

0.00 Credits

1 Chapter

Pharmacology

Free

2026 SPS Twin Cities | Formulary Management as a Value Strategy Engine in Both Acute and Ambulatory Settings

0.00 Credits

1 Chapter

Pharmacology

Free

$2026 SPS Twin Cities | Emerging Therapies in Relapsed/Refractory Follicular Lymphoma$

2026 SPS Twin Cities | Emerging Therapies in Relapsed/Refractory Follicular Lymphoma

0.00 Credits

1 Chapter

Pharmacology

Free

Contact Us

Learning Hub Central

Pharmacology

2026 SPS Seattle | 505(b)(2): From Opportunity Assessment to Implementation Best Practices

2026 SPS Seattle | HER’s First – Zongertinib’s Push to First-Line Setting in HER2 Positive Non-Small Cell Lung Cancer

2026 SPS Seattle | Expanding the Myasthenia Gravis Treatment Landscape: Introduction to Nipocalimab

2026 SPS Seattle | Isatuximab Subcutaneous by On-Body Injector vs. Isatuximab Intravenous Plus Pomalidomide & Dexamethasone

2026 SPS Seattle | Expanding the Horizon: Sunvozertinib in NSCLC with EGFR Exon 20 Insertions

2026 SPS Seattle | Make Way for HER, Datopotamab Deruxtecan Use in Breast Cancer and Non-Small Cell Lung Cancer

2026 SPS Seattle | HELIOS B Clinical Trial: Vutrisiran in the Management of Transthyretin-Mediated Amyloidosis Cardiomyopathy Patients

2026 SPS Seattle | Gedatolisib: A New Therapeutic Option in HR+/HER2− Advanced Breast Cancer

2026 SPS Seattle | The Role of Artificial Intelligence (AI) in Drug Formulary Management

2026 SPS Seattle | Caplacizumab in the Management of Thrombotic Thrombocytopenic Purpura, A Review of Real-World Evidence & MAYARI Clinical Trial

2026 SPS Seattle | Taletrectinib Pushing Progression-Free-Survival (PFS) Boundaries in the ROS1+ Non-Small Cell Lung Cancer Setting (NSCLC)

2026 SPS Seattle | Measuring the Impact of Specialty Clinical Pharmacists

2026 SPS Seattle | CMS Drug Price Negotiations, Site Neutrality and Proposed ASP – 33.4%; Waves of Provider Reimbursement Cuts

2026 SPS Twin Cities | Hyaluronidase Delivering New Subcutaneous Dosage Forms Throughout Various Therapeutic Areas: A Dive into Clinical, Safety, Practice and Economic Considerations

2026 SPS Twin Cities | CMS Drug Price Negotiations Through Maximum Fair Price (MFP): Access & Practice Considerations Now & Then

2026 SPS Twin Cities | Datopotamab Deruxtecan Therapy Considerations in the Management of Unresectable or Metastatic Hormone Receptor-Positive

2026 SPS Twin Cities | The Evolving Role of Caplacizumab in the Management of Thrombotic Thrombocytopenic Purpura (TTP)

2026 SPS Twin Cities | Beyond FOLFIRINOX: Updates in the Pancreatic Cancer Space

2026 SPS Twin Cities | Treosulfan Clinical and Practice Considerations in the Management of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome

2026 SPS Twin Cities | Gedatolisib in the Management of HR+/HER2-/PIK3CA Wild-Type Advanced Breast Cancer

2026 SPS Twin Cities | Emerging 505(b)(2) Therapeutic Optionality: From Opportunity Assessment to Implementation Best Practices

2026 SPS Twin Cities | Telisotuzumab Clinical Considerations in the Management of Non-Small Cell Lung Cancer (NSCLC)

2026 SPS Twin Cities | Beyond Steroids: Precision Biologic Approaches to Immune Related Adverse Event Management

2026 SPS Twin Cities | Formulary Management as a Value Strategy Engine in Both Acute and Ambulatory Settings

2026 SPS Twin Cities | Emerging Therapies in Relapsed/Refractory Follicular Lymphoma

Contact Us